Group B streptococcal infection epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Early-Onset GBS Disease===
===GBS in Neonates===
GBS is the leading infectious cause of [[morbidity]] and mortality among infants in the United States. As a result of prevention efforts, incidence of GBS has declined dramatically over the past 15 years, from 1.7 cases per 1,000 live births in the early 1990s to 0.34--0.37 cases per 1,000 live births in recent years. On the basis of data from CDC's Active Bacterial Core surveillance (ABCs) system, a network of 10 sites across the United States that conduct active, population-based surveillance, CDC estimates that in recent years, GBS has caused approximately 1,200 cases of early-onset invasive disease per year;<ref name=CDCsurveillance>CDC. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at [http://www.cdc.gov/abcs/reports-findings/survreports/gbs08.html cdc.gov].</ref> approximately 70% of cases are among babies born at term (≥37 weeks' gestation)..<ref name="pmid18460666">{{cite journal| author=Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al.| title=Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. | journal=JAMA | year= 2008 | volume= 299 | issue= 17 | pages= 2056-65 | pmid=18460666 | doi=10.1001/jama.299.17.2056 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18460666  }} </ref>
GBS is the leading infectious cause of [[morbidity]] and mortality among infants in the United States. As a result of prevention efforts, incidence of GBS has declined dramatically over the past 15 years, from 1.7 cases per 1,000 live births in the early 1990s to 0.34--0.37 cases per 1,000 live births in recent years. On the basis of data from CDC's Active Bacterial Core surveillance (ABCs) system, a network of 10 sites across the United States that conduct active, population-based surveillance, CDC estimates that in recent years, GBS has caused approximately 1,200 cases of early-onset invasive disease per year;<ref name=CDCsurveillance>CDC. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at [http://www.cdc.gov/abcs/reports-findings/survreports/gbs08.html cdc.gov].</ref> approximately 70% of cases are among babies born at term (≥37 weeks' gestation)..<ref name="pmid18460666">{{cite journal| author=Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al.| title=Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. | journal=JAMA | year= 2008 | volume= 299 | issue= 17 | pages= 2056-65 | pmid=18460666 | doi=10.1001/jama.299.17.2056 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18460666  }} </ref>


The case-fatality ratio of early-onset disease has declined from as high as 50% in the 1970s<ref name="pmid4608888">{{cite journal| author=Baker CJ, Barrett FF| title=Group B streptococcal infections in infants. The importance of the various serotypes. | journal=JAMA | year= 1974 | volume= 230 | issue= 8 | pages= 1158-60 | pmid=4608888 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4608888  }} </ref> to 4%--6% in recent years, primarily because of advances in neonatal care.<ref name="pmid18460666">{{cite journal| author=Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al.| title=Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. | journal=JAMA | year= 2008 | volume= 299 | issue= 17 | pages= 2056-65 | pmid=18460666 | doi=10.1001/jama.299.17.2056 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18460666  }} </ref><ref name="pmid10620644">{{cite journal| author=Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB et al.| title=Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. | journal=N Engl J Med | year= 2000 | volume= 342 | issue= 1 | pages= 15-20 | pmid=10620644 | doi=10.1056/NEJM200001063420103 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10620644  }} </ref>  Mortality is higher among preterm infants, with case-fatality rates of approximately 20% and as high as 30% among those ≤33 weeks' gestation, compared with 2%--3% among full-term infants.<ref name="pmid18460666">{{cite journal| author=Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al.| title=Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. | journal=JAMA | year= 2008 | volume= 299 | issue= 17 | pages= 2056-65 | pmid=18460666 | doi=10.1001/jama.299.17.2056 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18460666  }} </ref><ref name="pmid10620644">{{cite journal| author=Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB et al.| title=Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. | journal=N Engl J Med | year= 2000 | volume= 342 | issue= 1 | pages= 15-20 | pmid=10620644 | doi=10.1056/NEJM200001063420103 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10620644  }} </ref>
The case-fatality ratio of early-onset disease has declined from as high as 50% in the 1970s<ref name="pmid4608888">{{cite journal| author=Baker CJ, Barrett FF| title=Group B streptococcal infections in infants. The importance of the various serotypes. | journal=JAMA | year= 1974 | volume= 230 | issue= 8 | pages= 1158-60 | pmid=4608888 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4608888  }} </ref> to 4%--6% in recent years, primarily because of advances in neonatal care.<ref name="pmid18460666">{{cite journal| author=Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al.| title=Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. | journal=JAMA | year= 2008 | volume= 299 | issue= 17 | pages= 2056-65 | pmid=18460666 | doi=10.1001/jama.299.17.2056 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18460666  }} </ref><ref name="pmid10620644">{{cite journal| author=Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB et al.| title=Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. | journal=N Engl J Med | year= 2000 | volume= 342 | issue= 1 | pages= 15-20 | pmid=10620644 | doi=10.1056/NEJM200001063420103 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10620644  }} </ref>  [[Mortality]] is higher among preterm infants, with case-fatality rates of approximately 20% and as high as 30% among those ≤33 weeks' gestation, compared with 2%--3% among full-term infants.<ref name="pmid18460666">{{cite journal| author=Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S et al.| title=Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. | journal=JAMA | year= 2008 | volume= 299 | issue= 17 | pages= 2056-65 | pmid=18460666 | doi=10.1001/jama.299.17.2056 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18460666  }} </ref><ref name="pmid10620644">{{cite journal| author=Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB et al.| title=Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. | journal=N Engl J Med | year= 2000 | volume= 342 | issue= 1 | pages= 15-20 | pmid=10620644 | doi=10.1056/NEJM200001063420103 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10620644  }} </ref>


==References==
==References==

Revision as of 18:50, 19 August 2014

Group B Streptococcal Infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Group B Streptococcal Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Group B streptococcal infection epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Group B streptococcal infection epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Group B streptococcal infection epidemiology and demographics

CDC on Group B streptococcal infection epidemiology and demographics

Group B streptococcal infection epidemiology and demographics in the news

Blogs on Group B streptococcal infection epidemiology and demographics

Directions to Hospitals Treating Group B streptococcal infection

Risk calculators and risk factors for Group B streptococcal infection epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [4]

Overview

Group B Streptococcus (GBS) causes invasive disease primarily in infants, pregnant or postpartum women, and older adults, with the highest incidence among young infants.[1] Before active prevention was initiated, an estimated 7,500 cases of neonatal GBS disease occurred annually in the United States.[2] Striking declines in disease incidence coincided with increased prevention activities in the 1990s,[3] and a further reduction occurred following the issuance of the recommendation for universal screening in 2002.[4] However, GBS disease remains the leading infectious cause of morbidity and mortality among newborns in the United States.[1][5] The continued burden of disease and newly available data relevant to early-onset GBS disease prevention from the fields of epidemiology, obstetrics, neonatology, microbiology, molecular biology, and pharmacology prompted revision of the guidelines for early-onset GBS disease prevention.[6]

Epidemiology and Demographics

GBS in Neonates

GBS is the leading infectious cause of morbidity and mortality among infants in the United States. As a result of prevention efforts, incidence of GBS has declined dramatically over the past 15 years, from 1.7 cases per 1,000 live births in the early 1990s to 0.34--0.37 cases per 1,000 live births in recent years. On the basis of data from CDC's Active Bacterial Core surveillance (ABCs) system, a network of 10 sites across the United States that conduct active, population-based surveillance, CDC estimates that in recent years, GBS has caused approximately 1,200 cases of early-onset invasive disease per year;[7] approximately 70% of cases are among babies born at term (≥37 weeks' gestation)..[1]

The case-fatality ratio of early-onset disease has declined from as high as 50% in the 1970s[8] to 4%--6% in recent years, primarily because of advances in neonatal care.[1][3] Mortality is higher among preterm infants, with case-fatality rates of approximately 20% and as high as 30% among those ≤33 weeks' gestation, compared with 2%--3% among full-term infants.[1][3]

References

  1. 1.0 1.1 1.2 1.3 1.4 Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S; et al. (2008). "Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005". JAMA. 299 (17): 2056–65. doi:10.1001/jama.299.17.2056. PMID 18460666.
  2. Zangwill KM, Schuchat A, Wenger JD (1992). "Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system". MMWR CDC Surveill Summ. 41 (6): 25–32. PMID 1470102.
  3. 3.0 3.1 3.2 Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB; et al. (2000). "Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis". N Engl J Med. 342 (1): 15–20. doi:10.1056/NEJM200001063420103. PMID 10620644.
  4. CDC. Perinatal group B streptococcal disease after universal screening recommendations---United States, 2003--2005. MMWR 2007;56:701--5.[1]
  5. CDC. Trends in perinatal group B streptococcal disease---United States, 2000--2006. MMWR 2009;58:109--12.[2]
  6. Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.CDC.gov
  7. CDC. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at cdc.gov.
  8. Baker CJ, Barrett FF (1974). "Group B streptococcal infections in infants. The importance of the various serotypes". JAMA. 230 (8): 1158–60. PMID 4608888.

Template:Bacterial diseases


Template:WikiDoc Sources